Clinical usefulness of ranitidine in giant gastric ulcer.
We define "giant" gastric ulcer as a chronic gastric ulcer, with a diameter greater than or equal to 3 cm. Treatment of inpatients with several conventional antiulcer agents resulted in significantly lower healing rates in giant gastric ulcer than in "large" (greater than 15 and less than 30 mm diameter) or "medium" (greater than 5 and less than or equal to 15 mm diameter) ulcers. In 48 patients with giant gastric ulcers treated with ranitidine, cumulative endoscopic healing rates were: 0% after 2 weeks, 16.7% after 4 weeks, 50.0% after 6 weeks, 77.1% after 8 weeks, 85.4% after 10 weeks, and 87.5% after 12 weeks of treatment. Corresponding healing rates were determined for the control group, which included patients treated with various conventional antiulcer agents. Comparison of these results revealed that from the fourth week of treatment onward, healing rates of the ranitidine group were significantly higher than those of the control group. There was little difference in the cumulative healing rates in the ranitidine group. From these results, ranitidine is considered to be useful in the treatment of giant gastric ulcer.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D005773:Gastroscopy; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use*; D012737:Sex Factors; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000473:pathology
D000897:Anti-Ulcer Agents; D011899:Ranitidine